DAP Seminar: Unveiling critical nodes across KRAS-driven tumors: killing two (or three) birds with one stone

Silve Vicent graduated from the University of Navarra in Pamplona (Spain), where he later his doctoral degree under the supervision of Professor Luis Montuenga at the Department of Histology and Pathology, focusing on the characterization of the MAPK family and its negative feed-back regulators in lung cancer. He then took a postdoctoral position at the Center for Applied Medical Research (CIMA) in the Adhesion and Metastasis lab, where he studied the cellular and molecular mechanisms implicated in lung cancer metastasis to bone. After two years, he moved to Dr. Alejandro Sweet-Cordero's lab in the Cancer Biology Program at Stanford University. There he developed innovative RNAi-based, functional-genomics approaches and generated new genetically-engineered mouse models of lung cancer to identify synthetic lethal interactions in KRAS tumors and to investigate the role of tumor microenvironment in lung cancer progression.

In July 2012, Dr. Vicent joined the Program in Solid Tumors at CIMA and since 2013 he leads the Oncogenes and Effector Targets group in CIMA. He is also an Associated Lecturer at the University of Navarra. His group focuses on identifying functional nodes involved in cancer initiation and progression driven by KRAS oncogene, and unveiling new therapeutic strategies for the treatment of mutant KRAS tumors.